{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:40:28Z","timestamp":1792813228819,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","fertstert.org","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.fertnstert.2024.05.143","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T01:31:16Z","timestamp":1715650276000},"page":"445-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Individualized dosing of follitropin delta affects live birth and safety in in\u00a0vitro fertilization treatment: an individual participant data meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9099-3047","authenticated-orcid":false,"given":"Scott M.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karema","family":"Alrashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2024.05.143_bib1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1210\/er.2005-0015","article-title":"The science behind 25 years of ovarian stimulation for in\u00a0vitro fertilization","volume":"27","author":"Macklon","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib2","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","volume":"2020","author":"Ovarian Stimulation","year":"2020","journal-title":"Hum Reprod Open"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib3","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","article-title":"Medicine PCotASfR. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"106","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib4","first-page":"370","article-title":"The physiology and clinical utility of anti\u2013M\u00fcllerian hormone in women","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum Reprod Open"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/humupd\/dmu062","article-title":"Technical and performance characteristics of anti-Mullerian hormone and antral follicle count as biomarkers of ovarian response","volume":"21","author":"Iliodromiti","year":"2015","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/humupd\/dms041","article-title":"Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach","volume":"19","author":"Broer","year":"2013","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib7","first-page":"Cd012693","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in\u00a0vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI)","volume":"2","author":"Lensen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib8","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/jcph.328","article-title":"Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line","volume":"54","author":"Olsson","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib9","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.fertnstert.2014.08.013","article-title":"Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose-response trial in women undergoing in\u00a0vitro fertilization\/intracytoplasmic sperm injection","volume":"102","author":"Arce","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in\u00a0vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Andersen","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Japanese Follitropin Delta P. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial","volume":"42","author":"Ishihara","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib12","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1093\/humrep\/deab155","article-title":"A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients","volume":"36","author":"Qiao","year":"2021","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.rbmo.2019.11.013","article-title":"Ethnic discordance in serum anti-M\u00fcllerian hormone in healthy women: a population study from China and Europe","volume":"40","author":"Nelson","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib14","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.rbmo.2022.06.023","article-title":"Ethnic discordance in serum anti-M\u00fcllerian hormone in European and Indian healthy women and Indian infertile women","volume":"45","author":"Gromski","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib15","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib17","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.fertnstert.2014.03.026","article-title":"Live birth is the correct outcome for clinical trials evaluating therapy for the infertile couple","volume":"101","author":"Barnhart","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib19","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/humrep\/dex063","article-title":"Developments in IVF warrant the adoption of new performance indicators for ART clinics, but do not justify the abandonment of patient-centred measures","volume":"32","author":"Wilkinson","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/humrep\/deg081","article-title":"Risks and complications in assisted reproduction techniques: report of an ESHRE consensus meeting","volume":"18","author":"Land","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib22","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2019"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.32614\/RJ-2017-066","article-title":"glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling","volume":"9","author":"Brooks","year":"2017","journal-title":"RJ"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib24","article-title":"emmeans: estimated marginal means, aka least-squares means. 2023","volume":"1","author":"Lenth","year":"2023","journal-title":"R package version"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"brms: An R package for Bayesian multilevel models using Stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/humrep\/den480","article-title":"Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception","volume":"24","author":"Nelson","year":"2009","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rbmo.2011.04.002","article-title":"Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response","volume":"23","author":"Ledger","year":"2011","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib29","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0015-0282(16)55276-5","article-title":"Body weight, body mass index, and age: predictors of menotropin dose and cycle outcome in polycystic ovarian syndrome?","volume":"58","author":"McClure","year":"1992","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40261-022-01232-9","article-title":"Pharmacokinetics and safety of follitropin delta in gonadotropin down-regulated healthy Chinese women","volume":"43","author":"Shao","year":"2023","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40261-015-0276-8","article-title":"Dose-exposure proportionality of a novel recombinant follicle-stimulating hormone (rFSH), FE 999049, derived from a human cell line, with comparison between Caucasian and Japanese women after subcutaneous administration","volume":"35","author":"Olsson","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpobgyn.2022.102301","article-title":"Treatment algorithms for high responders: what we can learn from randomized controlled trials, real-world data and models","volume":"86","author":"Drakopoulos","year":"2023","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12958-021-00744-x","article-title":"Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017)","volume":"19","author":"Fatemi","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.742089","article-title":"Recombinant human follicle-stimulating hormone alfa dose adjustment in Us clinical practice: an observational, retrospective analysis of a real-world electronic medical records database","volume":"12","author":"Mahony","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.992677","article-title":"Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study)","volume":"13","author":"Blockeel","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/09513590.2020.1810659","article-title":"The interchangeability of two assays for the measurement of anti-M\u00fcllerian hormone when personalizing the dose of FSH in in-vitro fertilization cycles","volume":"37","author":"La Marca","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib37","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/humrep\/dex219","article-title":"Non-equivalence of anti-Mullerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing","volume":"32","author":"Iliodromiti","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.rbmo.2022.03.034","article-title":"Comparison between follitropin-delta and follitropin-alfa for ovarian stimulation in context of ART is only scientifically sound and clinically relevant if individualization of starting dose is allowed in both arms","volume":"45","author":"Montenegro Gouveia","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2024.05.143_bib39","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/humrep\/dex318","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 1: the predicted poor responder","volume":"32","author":"van Tilborg","year":"2017","journal-title":"Hum Reprod"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028224004539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028224004539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T02:32:29Z","timestamp":1727145149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028224004539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0015028224004539"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2024.05.143","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized dosing of follitropin delta affects live birth and safety in in\u00a0vitro fertilization treatment: an individual participant data meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2024.05.143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92024 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}